Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04998552 · ClinicalTrials.gov registry record · NA
Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
A NA study of Pancreas Adenocarcinoma, sponsored by Capital Health System.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04998552: Recruiting NA study of Pancreas Adenocarcinoma, sponsored by Capital Health System.
NCT04998552 is a NA study of Pancreas Adenocarcinoma that is actively recruiting participants, run by Capital Health System. The registered enrollment target is 10 participants, below the 78-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04998552, a NA study of Pancreas Adenocarcinoma, is actively recruiting participants, sponsored by Capital Health System.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
Primary Outcome
Occurrence of meeting resectability criteria using NCCN (PAN-C) guidelines
Conditions Studied
Interventions
- RADIATION Cyberknife
Study Locations (1)
New Jersey
- Capital Health Medical Center-Hopewell - Pennington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2027-06-22 |
| Phase | NA |
What NCT04998552 shows while recruiting
NCT04998552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 78-participant average among 10 other Pancreas Adenocarcinoma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Pancreas Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Cyberknife is the first listed.
NCT04998552 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04998552 about?
NCT04998552 is a clinical study titled "Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma". The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
What is the current status of trial NCT04998552?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2021-06-22. Estimated completion is 2027-06-22.
What conditions does trial NCT04998552 study?
This clinical trial studies the following conditions: Pancreas Adenocarcinoma.
What interventions are being tested in trial NCT04998552?
The interventions under investigation include: Cyberknife (RADIATION).
Who is sponsoring clinical trial NCT04998552?
This trial is sponsored by Capital Health System, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04998552 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04998552's enrollment target sits among peer trials
10 11th of 10 the lowest of 10 other Pancreas Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreas Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Genetic Testing Decision Aid
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
RECRUITING · Phase 2
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
RECRUITING · Phase 2
-
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI